Skip to main content

Table 4 Absolute mean changes in the development index of the MP-R scale at week 24

From: A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)

Age equivalents (months)

 

Group A (Placebo-Minocycline) (N = 11)

Group B1 (Minocycline-Placebo) (N = 11)

Group B2 (Minocycline- Minocycline) (N = 10)

p value

Primary endpoint: Absolute mean changes in the DI (age equivalent in months) of the MP-R Scale

Development index

Baseline

12·55 (6·53)

13·09 (6·31)

10·80 (6·33)

0·699

Week 24

14·80 (6·17)

13·00 (7·89)

7·80 (5·63)

0·689

Absolute mean change

1·30 (4·32)

−0·09 (3·93)

−3·00 (5·90)

0·139

Secondary analysis: Development index after 8-week wash-out period

Development index

Absolute mean change

−0·80 (3·39)

−1·00 (3·94)

−4·20 (8·79)

0·365

Age equivalents (months)

 

After 8 weeks from the suspension of Minocycline (N = 21)

After 16 weeks from the suspension of Minocycline (N = 11)

 

Absolute mean differences, 95% CI, p value

Development index

Absolute mean change

−0·94 (3·67)

−2·27 (4·12)

 

−1·32· 95% CI (− 1·65–4·30)